Researchers create a shelf-stable, inhalable COVID-19 vaccine that effectively targets the lungs

A recent study published in the Nature Biomedical Engineering journal illustrated a novel inhalable SARS-CoV-2 vaccine candidate centered on exosomes (Exos) coupled with recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD).

Related Keywords

United States ,American ,Randallb Terry Jr ,Emily Henderson ,American Heart Association ,National Institutes Of Health ,Carolina State University ,Duke University ,Distinguished Professor ,Regenerative Medicine ,Chapel Hill Joint Department ,Biomedical Engineering ,Chapel Hill ,Extracellular Vesicle ,Nature Biomedical ,National Institutes ,American Heart ,North Carolina State University ,Xsome Biotech ,Coronavirus Disease Covid 19 ,Vaccine ,Antibodies ,Fell ,Gold ,Cold Chain ,Coronavirus ,Nex Vivo ,Exosomes ,Maging ,Immune Response ,Immunity ,Liposomes ,Lungs ,Pandemic ,Athogen ,Eceptor ,Espiratory ,Ibonucleic Acid ,Cars ,Ars Cov 2 ,Evere Acute Respiratory ,Evere Acute Respiratory Syndrome ,Yndrome ,Virus ,